Adenovirus-retrovirus hybrid vectors achieve highly enhanced tumor transduction and antitumor efficacy in vivo

Molecular Therapy

Volumn 19, Issue 1, 2011, Pages 76-82

  Kubo, Shuji ^a,b   Haga, Kazunori ^b,e   Tamamoto, Atsuko ^a   Palmer, Donna J ^c   Ng, Philip ^c   Okamura, Haruki ^a   Kasahara, Noriyuki ^b,d  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Sanjukai Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; FLUCYTOSINE; ONCOLYTIC VIRUS; REPLICATION COMPETENT RETROVIRUS; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MURINE LEUKEMIA VIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; SOLID TUMOR; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS REPLICATION;

ADENOVIRIDAE; MURINE LEUKEMIA VIRUS;

EID: 78650871504     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.182     Document Type: Article

References (41)

1. Liu, TC and Kirn, D (2008). Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther 15: 877-884.
2. Logg, CR, Logg, A, Matusik, RJ, Bochner, BH and Kasahara, N (2002). Tissue-specifc transcriptional targeting of a replication-competent retroviral vector. J Virol 76: 12783-12791.
3. Logg, CR and Kasahara, N (2004). Retrovirus-mediated gene transfer to tumors: utilizing the replicative power of viruses to achieve highly effcient tumor transduction in vivo. Methods Mol Biol 246: 499-525.
4. Tai, CK, Wang, WJ, Chen, TC and Kasahara, N (2005). Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival beneft in experimental glioma. Mol Ther 12: 842-851.
5. Wang, WJ, Tai, CK, Kasahara, N and Chen, TC (2003). Highly effcient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors. Hum Gene Ther 14: 117-127.
6. Hiraoka, K, Kimura, T, Logg, CR and Kasahara, N (2006). Tumor-selective gene expression in a hepatic metastasis model after locoregional delivery of a replication-competent retrovirus vector. Clin Cancer Res 12: 7108-7116.
7. Hiraoka, K, Kimura, T, Logg, CR, Tai, CK, Haga, K, Lawson, GW et al. (2007). Therapeutic effcacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model. Cancer Res 67: 5345-5353.
8. Kikuchi, E, Menendez, S, Ozu, C, Ohori, M, Cordon-Cardo, C, Logg, CR et al. (2007). Highly effcient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors. Clin Cancer Res 13(15 Pt 1): 4511-4518.
9. Kikuchi, E, Menendez, S, Ozu, C, Ohori, M, Cordon-Cardo, C, Logg, CR et al. (2007). Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fudarabine phosphate and suppresses the growth of bladder tumor xenografts. Cancer Gene Ther 14: 279-286.
10. Bachrach, E, Duch, M, Pelegrin, M, Dreja, H, Pedersen, FS and Piechaczyk, M (2003). In vivo infection of mice by replication-competent MLV-based retroviral vectors. Methods Mol Med 76: 343-352.
11. Bachrach, E, Pelegrin, M, Piechaczyk, M, Pedersen, FS and Duch, M (2002). Effcient gene transfer into spleen cells of newborn mice by a replication-competent retroviral vector. Virology 293: 328-334.
12. Metzl, C, Mischek, D, Salmons, B, Günzburg, WH, Renner, M and Portsmouth, D (2006). Tissue- and tumor-specifc targeting of murine leukemia virus-based replication-competent retroviral vectors. J Virol 80: 7070-7078.
13. Solly, SK, Trajcevski, S, Frisén, C, Holzer, GW, Nelson, E, Clerc, B et al. (2003). Replicative retroviral vectors for cancer gene therapy. Cancer Gene Ther 10: 30-39.
14. Trajcevski, S, Solly, SK, Frisén, C, Trenado, A, Cosset, FL and Klatzmann, D (2005). Characterization of a semi-replicative gene delivery system allowing propagation of complementary defective retroviral vectors. J Gene Med 7: 276-287.
15. Qiao, J, Moreno, J, Sanchez-Perez, L, Kottke, T, Thompson, J, Caruso, M et al. (2006). VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment. Gene Ther 13: 1457-1470.
16. Dalba, C, Bellier, B, Kasahara, N and Klatzmann, D (2007). Replication-competent vectors and empty virus-like particles: new retroviral vector designs for cancer gene therapy or vaccines. Mol Ther 15: 457-466.
17. Paar, M, Schwab, S, Rosenfellner, D, Salmons, B, Günzburg, WH, Renner, M et al. (2007). Effects of viral strain, transgene position, and target cell type on replication kinetics, genomic stability, and transgene expression of replication-competent murine leukemia virus-based vectors. J Virol 81: 6973-6983.
18. Wang, W, Tai, CK, Kershaw, AD, Solly, SK, Klatzmann, D, Kasahara, N et al. (2006). Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model. Neurosurg Focus 20: E25.
19. Logg, CR, Tai, CK, Logg, A, Anderson, WF and Kasahara, N (2001). A uniquely stable replication-competent retrovirus vector achieves effcient gene delivery in vitro and in solid tumors. Hum Gene Ther 12: 921-932.
20. Kubo, S, Kataoka, M, Tateno, C, Yoshizato, K, Kawasaki, Y, Kimura, T et al. (2010). In vivo stable transduction of humanized liver tissue in chimeric mice via high-capacity adenovirus-lentivirus hybrid vector. Hum Gene Ther 21: 40-50.
21. Kubo, S and Mitani, K (2003). A new hybrid system capable of effcient lentiviral vector production and stable gene transfer mediated by a single helper-dependent adenoviral vector. J Virol 77: 2964-2971.
22. Kubo, S, Seleme, MC, Soifer, HS, Perez, JL, Moran, JV, Kazazian, HH Jr et al. (2006). L1 retrotransposition in nondividing and primary human somatic cells. Proc Natl Acad Sci USA 103: 8036-8041.
23. Soifer, H, Higo, C, Kazazian, HH Jr, Moran, JV, Mitani, K and Kasahara, N (2001). Stable integration of transgenes delivered by a retrotransposon- adenovirus hybrid vector. Hum Gene Ther 12: 1417-1428.
24. Soifer, H, Higo, C, Logg, CR, Jih, LJ, Shichinohe, T, Harboe-Schmidt, E et al. (2002). A novel, helper-dependent, adenovirus-retrovirus hybrid vector: stable transduction by a two-stage mechanism. Mol Ther 5(5 Pt 1): 599-608.
25. Ng, P, Beauchamp, C, Evelegh, C, Parks, R and Graham, FL (2001). Development of a FLP/frt system for generating helper-dependent adenoviral vectors. Mol Ther 3(5 Pt 1): 809-815.
26. Palmer, D and Ng, P (2003). Improved system for helper-dependent adenoviral vector production. Mol Ther 8: 846-852.
27. Palmer, DJ and Ng, P (2008). Methods for the production of helper-dependent adenoviral vectors. Methods Mol Biol 433: 33-53.
28. Umaña, P, Gerdes, CA, Stone, D, Davis, JR, Ward, D, Castro, MG et al. (2001). Effcient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination. Nat Biotechnol 19: 582-585.
29. Greber, UF, Webster, P, Weber, J and Helenius, A (1996). The role of the adenovirus protease on virus entry into cells. EMBO J 15: 1766-1777.
30. Kubo, S, Kiwaki, K, Awata, H, Katoh, H, Kanegae, Y, Saito, I et al. (1997). In vivo correction with recombinant adenovirus of 4-hydroxyphenylpyruvic acid dioxygenase defciencies in strain III mice. Hum Gene Ther 8: 65-71.
31. Lang, FF, Bruner, JM, Fuller, GN, Aldape, K, Prados, MD, Chang, S et al. (2003). Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 21: 2508-2518.
32. Campos, SK and Barry, MA (2007). Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther 7: 189-204.
33. Glasgow, JN, Bauerschmitz, GJ, Curiel, DT and Hemminki, A (2004). Transductional and transcriptional targeting of adenovirus for clinical applications. Curr Gene Ther 4: 1-14.
34. Volpers, C and Kochanek, S (2004). Adenoviral vectors for gene transfer and therapy. J Gene Med 6 Suppl 1: S164-S171.
35. Dalba, C, Klatzmann, D, Logg, CR and Kasahara, N (2005). Beyond oncolytic virotherapy: replication-competent retrovirus vectors for selective and stable transduction of tumors. Curr Gene Ther 5: 655-667.
36. Tai, CK and Kasahara, N (2008). Replication-competent retrovirus vectors for cancer gene therapy. Front Biosci 13: 3083-3095.
37. Graham, FL, Smiley, J, Russell, WC and Nairn, R (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36: 59-74.
38. Sena-Esteves, M, Saeki, Y, Camp, SM, Chiocca, EA and Breakefeld, XO (1999). Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons. J Virol 73: 10426-10439.
39. Kochanek, S, Clemens, PR, Mitani, K, Chen, HH, Chan, S and Caskey, CT (1996). A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci USA 93: 5731-5736.
40. Morsy, MA, Gu, M, Motzel, S, Zhao, J, Lin, J, Su, Q et al. (1998). An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA 95: 7866-7871.
41. Sandig, V, Youil, R, Bett, AJ, Franlin, LL, Oshima, M, Maione, D et al. (2000). Optimization of the helper-dependent adenovirus system for production and potency in vivo. Proc Natl Acad Sci USA 97: 1002-1007.